Figure 7.
Figure 7. CD4Treg TCRβ repertoire analysis in pediatric patients. (A) Hill-based diversity values for CD4Tregs from patients 1, 6, 11, and 12 at baseline, W8 or W16, and 6 months of IL-2 therapy. Each line represents an individual patient over time. (B) Correlation coefficients between the productive frequencies of the top 1000 clones at weeks 8 or 16 and the productive frequencies of the same clones at baseline for each cell type are shown for the 4 pediatric patients. (C) Number of clonotypes making up the top 20% of productive frequencies at baseline and after 8 to 16 weeks of IL-2 therapy. Each box within the large squares represents a unique clonotype, and the box size represents the relative proportion of that clonotype. Colors at baseline and W8-W16 do not represent the same clonotype. *P < .05, 2-sided Wilcoxon signed-rank test.

CD4Treg TCRβ repertoire analysis in pediatric patients. (A) Hill-based diversity values for CD4Tregs from patients 1, 6, 11, and 12 at baseline, W8 or W16, and 6 months of IL-2 therapy. Each line represents an individual patient over time. (B) Correlation coefficients between the productive frequencies of the top 1000 clones at weeks 8 or 16 and the productive frequencies of the same clones at baseline for each cell type are shown for the 4 pediatric patients. (C) Number of clonotypes making up the top 20% of productive frequencies at baseline and after 8 to 16 weeks of IL-2 therapy. Each box within the large squares represents a unique clonotype, and the box size represents the relative proportion of that clonotype. Colors at baseline and W8-W16 do not represent the same clonotype. *P < .05, 2-sided Wilcoxon signed-rank test.

Close Modal

or Create an Account

Close Modal
Close Modal